News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Immunic chief medical officer discusses promising treatments to mark World IBD Day

Immunic Inc

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses Inflammatory Bowel Disease (IBD) with Proactive's Stephen Gunnion to mark World IBD Day on May 19. Muehler explained that IBD encompasses Crohn's disease and ulcerative colitis, characterised by an immune response triggered by the interaction between gut bacteria and the immune system, leading to bowel wall damage and ulcerations. This condition affects 1-2% of the population, presenting significant social challenges due to symptoms like diarrhoea and abdominal pain, which can limit social and professional activities. Currently, IBD is managed with immunosuppressive drugs, which, while effective, increase susceptibility to infections and other autoimmune diseases and often show immunosuppression. Dr Muehler highlighted the need for treatments that do not suppress the immune system. Immunic Inc. has been exploring new therapies, including a drug that strengthens the bowel barrier. A recent phase two trial with Vidofludimus calcium (IMU-838) in ulcerative colitis showed promising results in maintaining remission. This drug, primarily tested in multiple sclerosis, is part of a class not previously tested in large IBD trials. Another promising drug, IMU-856, aims to regenerate the bowel barrier, preventing harmful interactions between gut bacteria and the immune system without immunosuppression. This drug has shown positive results in animal experiments as well as in healthy volunteers and celiac disease trials. Immunic currently evaluates potential testing of IMU-856 in IBD. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

May 17, 2024 02:35 PM Eastern Daylight Time

Video
Article thumbnail News Release

Tackling Childhood Peanut Allergies

YourUpdateTV

Right now, more children in the U.S. are living with peanut allergy than ever before, and approximately 75% will not outgrow their allergy. Recently, Pediatric Allergist, Dr. Douglas Mack, and Sarah Korieshi, the Mother of a peanut allergic child, participated in a nationwide satellite media tour to discuss the impact on children and innovative new treatment options that can help. A video accompanying this announcement is available at: https://youtu.be/5uKicnsGHv8 The repercussions of this condition are profound, extending beyond mere dietary restrictions to impacting a child's daily life, social interactions, and overall well-being. The constant fear of accidental exposure and the potential for severe allergic reactions can also be extremely difficult for families to navigate. The increase in prevalence over the past 20 years has driven a growing need for effective treatment options to manage the condition. For doctors, that means treatments that reduces the likelihood of an allergic reaction in the case of accidental exposure, and treatments that work within the lifestyle of the child and family. The good news is that recent years have brought about a spate of new innovations in the allergy space. For example, there is currently an ongoing clinical trial evaluating Viaskin TM Peanut, a patch containing the equivalent of one one-thousandth of one peanut kernel. The patch is applied each day to a child’s back in order to build up a tolerance to peanut protein, making it less likely that a child will have a reaction after an accidental exposure. For parents, a treatment like this would be life-changing, as a non-invasive option – something that can be incorporated into our busy lives, without any restrictions to regular activities. Having access to a treatment option that allows children and parents to participate in typical activities for a child, such as birthday parties, sports activities, attending camp, or even school, would give parents peace of mind and children the care-free life they deserve. For more information, visit vitesseallergystudy.com About Dr. Douglas Mack Dr. Mack is co-author of clinical guidelines on the prevention of allergy, oral immunotherapy and anaphylaxis and focuses on oral immunotherapy for food at Halton Pediatric Allergy clinic. Dr. Douglas Mack has been a pediatric allergy, asthma, and immunology specialist for over 10 years. Dr. Mack is an assistant clinical professor in the Department of Pediatrics at McMaster University and is an affiliate of Sick Kids. He sits on the board of directors at the Canadian Society of Allergy and Clinical Immunology. He is co-author of clinical guidelines on the prevention of allergy, oral immunotherapy, and anaphylaxis. Dr. Mack is co-founder of Halton Pediatric Allergy clinic where his focus is on oral immunotherapy for food. About Sarah Korieshi Sarah learned that her daughter Zara had a deadly peanut allergy when she was just 9 months old. The first thing she thought was, not only how life-threatening eating a food can be, but also living with the constant fear of what may happen every time she eats. There has always been constant fear with how unpredictable a reaction can be, and the anxiety that comes with solely relying on avoidance really takes a toll. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 17, 2024 10:09 AM Eastern Daylight Time

Video
Article thumbnail News Release

Neural Therapeutics CEO Ian Campbell discusses potential CSE listing and future plans

Neural Therapeutics Inc.

Neural Therapeutics CEO Ian Campbell discusses the company's conditional approval to list on the Canadian Securities Exchange (CSC) in an interview with Proactive's Stephen Gunnion. Campbell explained that the CSE listing is a strategic move, enabling broader market participation and capitalisation on its advancements. The company aims to raise $500,000, primarily for research and development efforts and securing intellectual property, including two patents. Campbell highlighted the growing interest in psychedelic treatments, noting the significant investment in this sector and the 44% rise of the Psychedelic Invest Index this year. He emphasised the mental health crisis and the inadequacy of outdated therapies, positioning psychedelics as a promising and disruptive alternative. Neural Therapeutics specialises in mescaline extracted from the San Pedro cactus, a substance with a long history of safe use. Campbell noted mescaline's unique properties, such as its longer duration in the body, which supports neuroplasticity and potential treatment for mental illnesses like addiction without causing hallucinations. The CSE listing is expected to enhance the company's visibility, attract investment, and accelerate drug development. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

May 17, 2024 08:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

The HERizon Disposable Hysteroscope aims to redefine industry standards

Minerva Surgical, Inc.

Minerva Surgical announces the immediate and exclusive distribution of a new disposable hysteroscope that will be displayed at the Annual Clinical & Scientific Meeting of American College of Obstetricians and Gynecologists in San Francisco, CA. The company plans to soon rebrand the new disposable hysteroscope as HER izon, and their goal is to redefine the standards of efficiency and accessibility in gynecological care. “This marks a significant milestone in the company’s mission to address the needs of gynecologists and further advance Women’s Health,” states Minerva Surgical Chief Medical Officer Eugene Skalnyi, M.D. “ HER izon embodies versatility as a hysteroscope, facilitating an array of procedures both in the operating room and office settings. It is one of a few technologies that our team plans to launch to better serve the evolving patterns in Gynecology.” The HER izon Disposable Hysteroscope is a cutting-edge system that is introduced in alignment with ACOG and AAGL's advocacy for the elimination of blind assessment practices in the uterine cavity. Several key features of the HER izon Disposable Hysteroscope include. 1. Disposable Design: Single-use hysteroscope eliminates the need for traditional hysteroscope reprocessing, reduces the risk of cross-contamination, and ensures compliance with sterility standards. 2. Angled Cannula Tip: Provides rigidity to help enter the cervical canal and articulation to navigate an array of uterine cavity positions. 3. Compact Footprint: 4.8mm outer diameter sheath requires minimal or no dilation and 6Fr working channel allows for a broad spectrum of procedures such as direct visualization polypectomy, endometrial biopsy, D&C, and IUD removal. 4. User-Friendly Interface: High-Definition image technology, two LED lights provide bright and clear visualization, and the intuitive interface enables seamless system navigation. Dr. David Glassman, DO FACOG EMIGS, a prominent gynecologist in Phoenix, Arizona, shared his excitement about the new HER izon Disposable Hysteroscope, stating, “ HER izon is a revolutionary advancement in hysteroscopy technology. Designed with precision and patient comfort in mind, HER izon offers unparalleled clarity and control, providing healthcare professionals with a clearer view and easier access to the uterine cavity. Its innovative features enhance procedural efficiency, reducing both patient discomfort and procedure times. With HER izon, healthcare providers can elevate their practice, delivering superior care and empowering women to take control of their health with confidence.” The introduction of the HER izon Disposable Hysteroscope underscores Minerva Surgical’s commitment to providing gynecologists with solutions that improve patient outcomes. About Minerva Surgical, Inc. Minerva Surgical is a commercial-stage medical technology company focused on developing, manufacturing, distributing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. The Company has established a broad product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. The Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. For more information about the HER izon Disposable Hysteroscope and other innovative medical devices from Minerva Surgical, please visit www.MinervaSurgical.com. The disposable hysteroscope is manufactured by Jiyuan Medical. Contact Details Minerva Surgical Kevin Tracey +1 855-646-7874 media@minervasurgical.com Company Website https://minervasurgical.com/

May 16, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

UNOS applauds passage of FAA reauthorization bill

United Network for Organ Sharing

Today, the United Network for Organ Sharing (UNOS) issued its support of Congress’ passage of the bipartisan, bicameral Federal Aviation Administration (FAA) reauthorization bill, which includes a provision to improve the safety and efficiency of the transportation of donor organs through the nation’s commercial aviation system. The bill now heads to the president’s desk for signature. The Securing Growth and Robust Leadership in American Aviation Act requires the Department of Transportation (DOT), in consultation with the FAA, to convene a working group to develop best practices for transporting organs in the cabin of a commercial aircraft. The working group will include organ procurement organizations, transplant hospitals, commercial airlines, flight attendants and other federal agencies. DOT is required to convene the working group no later than 90 days after the bill is enacted. No later than one year after convening, the working group must present recommendations to the secretary of DOT. Before the September 11 attacks, organs – primarily kidneys – were transported within a commercial flight’s main cabin under supervision of the aircrew. The attacks prompted significant changes to airport protocols, including removing transplant professionals’ ability to accompany an organ through security without an airplane ticket. As a result, organs currently travel in the cargo hold and are subject to cargo business hours, which vary between airlines and are impacted by staffing shortages. Organs arriving when a cargo office is closed sit on ice for prolonged periods, increasing the potential for an organ not to be used. “Ensuring a donated organ gets to a patient on time and safely is absolutely critical, which is why UNOS has been working with the donation and transplant community and Congress to create a process to bring organs out of the cargo hold and back into the cabin of an airplane,” said Maureen McBride, Ph.D., CEO of UNOS. “Thank you to those working with us to advocate for change and include this provision in the FAA reauthorization package, namely Senators Ron Wyden, Maria Cantwell, Ted Cruz, and John Thune, and Reps. Bruce Westerman, Greg Stanton, Beth Van Duyne, Sam Graves, and Rick Larsen. The bill’s passage highlights the bipartisan consensus and understanding of the lifesaving importance of this issue. I appreciate the commitment to honor the gift of life and do right by patients on the waitlist, generous donors, and their families. I look forward to working with the Department of Transportation to bring organs back into the cabin of an aircraft.” Transportation is a cornerstone of the UNOS Action Agenda, a series of recommendations to strengthen the U.S. donation and transplant system. To further reduce the risk of delaying or damaging organs in transport, UNOS also recommends the next contracts for the Organ Procurement and Transplantation Network (OPTN) should require the use of physical trackers for unaccompanied donor organs recovered for transplant, and the establishment of a centralized organ tracking system. “Donations and transplants are going up across the country, and so are the number of organs traveling every hour of every day,” said McBride. “This community owes it to patients and donor families to ensure that organs travel as safely and efficiently as possible. Every viable organ ultimately not transplanted represents a profound loss.” The provision included in the FAA reauthorization bill is the result of ongoing advocacy by UNOS and other members of the nation’s organ donation and transplant community. Since 2022, UNOS has engaged with FAA leadership, the Transportation Security Administration and the House and Senate to pursue this reform. Actions to move organs back to the airplane cabin and out of cargo are widely endorsed by the donation and transplant community, including the American Association of Kidney Patients, American Foundation for Donation & Transplantation, American Kidney Fund, American Society of Histocompatibility and Immunogenetics, American Society of Nephrology, American Society of Transplantation, American Society of Transplant Surgeons, Association of Organ Procurement Organizations, Donate Life America, Donate Life Virginia, Kidney Care Partners, Kidney Transplant Collaborative, National Kidney Foundation, Nationwide Organ Recovery Transport Alliance, North American Transplant Coordinators Organization, Organ Donation Advocacy Group, Renal Physicians Association, Transplant Recipients International Organization, Transplant Families, Transplant Unwrapped, and Waitlist Zero. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

May 15, 2024 02:53 PM Eastern Daylight Time

Article thumbnail News Release

FOR IMMEDIATE RELEASE

Apple Rush Company, Inc.

Apple Rush Company, Inc. (Otcpink:APRU), a leading player in the functional beverage industry, proudly announces it has cleared up final details of brand ownership with Bob Corr and Corr Brands, Inc. Tony Torgerud, CEO of Apple Rush, has negotiated a historical closing on the rights and trademarks of Corr Brands, Inc. In the transaction, Bob Corr has agreed to transfer the rights of the Corr Brands, Inc. trademarks and to forgo any royalties from previous agreements to give Tony and Apple Rush the best opportunity to succeed moving forward. Tony Torgerud said, “I have been negotiating for a year with Bob and he finally felt it was time to work out an agreement that would benefit everyone. Over the next couple months, all the required paperwork will be filed for transference and updates on all intellectual property held by Corr Brands, Inc. Not having to pay royalties will add thousands to the bottom line.” This agreement solidifies the future of the “Rush” family of brands that have been in the market since 1972. Bob Corr stated, “I want to see Apple Rush succeed and I feel the timing is right to get this deal done. I retired a long time ago and it is now time to write the next chapters of this story and with Apple Rush having its own production capabilities and its own tunnel pasteurizer, it is an opportunity that shouldn’t be wasted. I have given up hundreds of thousands of dollars in royalties, licensing fees and shares to enhance shareholder value.” With our pilot production abilities, we hope to do some reformulations to introduce a 2024 version of Ginseng Rush and the relaunch of the original Apple Rush flavor line. Apple Rush has held a license for 13 states and International distribution for the last 8 years and now owns the IP without paying the $5,000 per state license, another bottom line gain for all of our stockholders. About The Apple Rush Company, Inc. The Apple Rush Company, Inc., through its subsidiary APRU, LLC, is a distributor of CPG products under the trademarked Apple Rush brand, Element brand and other labels. The Apple Rush brand has more than 50 years of existence in the natural beverage industry. As a historical leader in the organic and natural beverage sector our goal is to now become a leader in the distribution of anhydrous hemp oil products nationwide. For more information, please go to www.aprubrands.com, www.element-brands.com, elementk.kratomwave.store www.alkhemicalroots.com with our expanded product portfolio. Safe Harbor Act: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter forward-looking statements, whether as a result of new information, future events or otherwise. Contact Details Apple Rush Company, Inc. Tony Torgerud +1 888-741-3777 dtorgerud@aprullc.com Company Website http://www.aprubrands.com

May 14, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

College of American Pathologists: Cancer Rates Soaring in Younger Adults

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/rq8XcHBnPw0 Cancer doesn’t discriminate by age today. Consider celebrities like Chadwick Boseman, who died from colon cancer; Olivia Munn, who recently underwent a double mastectomy; Ninja, a popular streamer on Twitch diagnosed with skin cancer; and Catherine, the Princess of Wales, who is currently being treated for the disease. All of them were diagnosed before the age of 50. Why is this happening and what can we do to catch it early? There are several reasons: diet, lifestyle, and environmental factors. The College of American Pathologists is emphasizing the importance of early detection, screening, and being vigilant regarding symptoms. A nationwide media tour was conducted to discuss this important issue featuring Dr. Donald Karcher, president of the College of American Pathologists. Topics that Dr. Karcher discussed included: · What is behind the soaring trend of younger adults being diagnosed with cancer? · What symptoms to look for to improve cancer outcomes. · What cancers can and should be screened for? · What if you don’t meet the minimum age requirements for screening but are having symptoms? · Discussing the importance of early detection. FOR MORE INFORMATION VISIT: YOURPATHOLOGIST.ORG Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 14, 2024 09:30 AM Eastern Daylight Time

Video
Article thumbnail News Release

Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results

Lisata Therapeutics Inc

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo tells Proactive's Stephen Gunnion that 2024 is a pivotal year for the oncology company, with Phase 2b ASCEND trial top-line data expected in the fourth quarter. Discussing the company's first-quarter milestones, Mazzo said the results are anticipated to be foundational for the company's future, potentially leading to provisional approval applications in Australia and subsequent discussions with the FDA and EMA. Mazzo highlighted Lisata's effective cash management, with over $43 million in funds ensuring operations into 2026. The company has achieved several regulatory milestones, including orphan designations for pancreatic cancer and glioma in the EU and US, and a rare pediatric disease designation for osteosarcoma in the US. Additionally, Mazzo discussed the rapid progress of the BOLSTER trial in cholangiocarcinoma, expected to provide early data points in 2025. The company plans to expand its trials and anticipates potential partnership announcements by year-end, driven by these developments. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

May 13, 2024 10:45 AM Eastern Daylight Time

Video
Article thumbnail News Release

Texas’ Leading Hormone Provider Expands Cutting-Edge Preventative Screening Tool to All Clinics

Forum Health

Hormones by Design, a Forum Health provider and leader in hormone replacement therapy, has acquired DITI Imaging – a pioneer in digital infrared thermal imaging. This strategic move combines the expertise of both companies to offer comprehensive and preventative health care to two of its five renown Texas locations. Learn more about Hormones by Design. Digital infrared thermal imaging (DITI) is a non-invasive, radiation-free screening tool to detect early signs of inflammation and abnormal blood flow patterns, which may be precursors to various health conditions. By identifying these indicators early, patients can proactively address potential issues before they develop into more serious conditions. Phil Hagerman, Forum Health CEO: “ With 1 in 8 women diagnosed with breast cancer and chronic inflammatory diseases on the rise, early detection is paramount. This acquisition underscores our commitment to advancing personalized, integrative healthcare and providing the latest, top-of-the-line technology to help our patients achieve optimal health.” DITI is the only screening tool capable of detecting inflammation and associated heat patterns unlike X-rays, mammograms, MRIs and ultrasound tests. Some of the many health conditions DITI can screen for are: Breast cancer Early indications of asymptomatic and systemic inflammatory and degenerative processes Systemic, artery, dental, and sinus inflammation Unexplained and referred pain, including arthritis and nerve damage Fibromyalgia and digestive disorders Overactive and underactive thyroid conditions Dr. Melissa Miskell, Hormones by Design founder: "We’re thrilled to welcome DITI Imaging into the Hormones by Design family. It allows us to expand our preventative healthcare offerings, better monitor the effects of hormone therapy, more comprehensively treat patients with thyroid conditions, and help people maintain optimal health as they age.” Patients will have access to advanced screening services, including breast, full-body, and region-specific imaging, in addition to personalized BHRT options. Schedule an appointment or find a Hormones by Design location near you. About Forum Health, LLC Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. Contact Details Forum Health Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

May 09, 2024 08:50 AM Eastern Daylight Time

12345 ... 165